Stock Data
$0.25 (0.80%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Stoke Therapeutics Inc is a pioneering biopharmaceutical firm focused on developing innovative treatments for severe genetic diseases. With a unique approach using antisense oligonucleotides, the company aims to restore protein levels in patients. Its leading projects include STK-002 for autosomal dominant optic atrophy and STK-001 for Dravet syndrome, among others targeting central nervous system and eye diseases. Based in Bedford, Massachusetts, Stoke Therapeutics has formed a significant partnership with Acadia Pharmaceuticals to advance RNA-based medicines for rare neurodevelopmental conditions.
Roughly $420 million in liquidity funds the rolling NDA starting Q1 2027 and a 2028 launch, with Phase 3 EMPEROR fully enrolled at 162 patients and zero discontinuations. R&D nearly doubled to $49.5 million, and the loss per share missed expectations as pre-commercial spending accelerated.
3 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
